CAS Name: androst-4-en-3-one, 17-[(1-oxoheptyl)-oxy]-, (17β)- androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17β)- 17-(1-Oxopropoxy)-(17b)-androst-4-en-3-one 17b-Hydroxyandrost-4-en-3-one decanoate
This is a testosterone injection consisting of a mix of propionate, phenylpropionate, isocaproate, and decanoate esters. Because of the mix of different esters, “4 Test Inj” has improved pharmacokinetics with the fast action of propionates and the prolonged action of longer isocaproate and decanoate esters, thus providing a more stable concentration of testosterone in the blood over a longer period of time.
Esterification of the 17-beta-hydroxy group by different esters can prolong of action of testosterone, because testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus “4 Test Inj” can be given at intervals of two to four weeks.
|each tablet contains:|
|Testosterone Propionate||BP||30 mg|
|Testosterone Phenylpropionate||60 mg|
|Testosterone Isocaproate||BP||60 mg|
|Testosterone Decanoate||BP||100 mg|
|Benzyl Alcohol||BP||5.0% v/v|
Packing: 10 mL Glass Vial
Dosage and administration
Adult dose (male): 200-400 mg per every 2 weeks intramuscularly
Adult dose (female in case of mammary cancer): 200 to 400 mg every 2 to 4 weeks intramuscularly
During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). In males: at large doses of exogenous androgens, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH). In females: virilization effects.